“It appears that, in phase III studies, in some subjects vaccinated with Vaxzevria (AstraZeneca), significantly milder or completely absent side effectsafter accidental administration of lower doses of the vaccine. In this sense, there are those who have assumed that, in the face of lower doses of vaccine, more contained immunological responses are activated and, for this reason, they are not able to evoke significant inflammatory reactions from which the production of antibody antibodies could arise. Platelet Factor 4, in turn capable of triggering the thrombotic reaction. “He explains it at the time.news Health immunologist Mauro Minelli, responsible for the South of the Italian Foundation of Personalized Medicine, which makes this proposal to relaunch the vaccination campaign.
“Collaterally – continues Minelli – the low degree of immune-induced inflammation from a less aggressive dose of vaccine seems to have contributed to generating levels of immunizing antibodies a little higher than those produced after full-dose AstraZeneca vaccination. , if these are the evidences that could, if anything, be confirmed by broader observational evaluations, because – suggests the immunologist – not to verify its feasibility in the field by making a virtue of necessity, given that the current availability of vaccines could not only generate fewer adverse events, but also allow twice as many citizens to be immunized? “.
As regards, however, the Johnson & Johnson vaccine, says immunologist Minelli to Ankronos Salute, “the completely unexpected and out of place interruption of the indispensable vaccination support provided by the expected J&J, as well as deeply undermining the certainties that all of us we had placed in the mass immunization plan, clearly highlights a substantial weakness of the European political representation that, without a logically acceptable reason, it slavishly aligns itself with American decisions“.
“For 6 thrombotic reactions, only one of them fatal, recorded in women aged 18 to 45 years after administration of Johnson & Johnson vaccine in the United States, where more than six million people had already been vaccinated (risk percentage equal to 0.000001%), Europe decides to ‘copy’ the choices of the US government effectively inhibiting the use of the doses that in the meantime had arrived on the continent “, adds the immunologist.
“One wonders, given the new evidence that seems to correlate the very rare immune-mediated heparin-like thromboembolic reactions to the viral vector, why suspend the use of the J&J vaccine – asks Minelli – if the vaccination with AstraZeneca continues, which, like the Johnson & Johnson, which has been suspended as a precaution, entrusts the transport of the genetic material of Sars-Cov-2 useful for immunization to an inactivated adenovirus? If the two vaccines are substantially the same, why two weights and two measures? ”
“It is clear that these choices, in addition to significantly compromising the effectiveness of the vaccination plan – he concludes – with its important load of positive expectations, alter even more the already precarious balance between disheartened citizens and the institution in difficulty in making decisions”.